肝硬化患者静脉与动脉血栓风险及结局:丹麦全国队列研究
该丹麦全国队列研究纳入5854例肝硬化门诊患者及23870名匹配对照,发现肝硬化患者静脉血栓栓塞和缺血性卒中风险升高,但急性心肌梗死风险未升高;血栓后90天死亡率肝硬化组更高,且接受抗血栓治疗更少。
要点
- 肝硬化患者静脉血栓栓塞和缺血性卒中风险较对照升高,急性心肌梗死风险未升高。
- 肝硬化失代偿仅增加急性心肌梗死风险,不增加其他血栓风险。
- 肝硬化患者血栓后90天死亡率更高,且接受抗血栓治疗更少。
核心结论
- 肝硬化患者静脉血栓栓塞和缺血性卒中风险增加,但急性心肌梗死风险未增加。
- 肝硬化患者发生血栓后90天死亡率高于对照,且接受抗血栓治疗更少。
研究设计与样本
- 基于丹麦全国医疗登记系统的队列研究,纳入5854例肝硬化门诊患者和23870名性别年龄匹配的对照。
- 随访至发生静脉血栓栓塞、急性心肌梗死、缺血性卒中或死亡。
主要发现
- 肝硬化患者1年内任何血栓事件绝对风险为0.8%,10年为6.3%。
- 肝硬化患者静脉血栓栓塞风险较对照升高(aHR 2.0;95%CI 1.5-2.6)。
- 肝硬化患者缺血性卒中风险较对照升高(aHR 1.7;95%CI 1.3-2.3)。
- 肝硬化患者急性心肌梗死风险较对照未升高(aHR 0.7;95%CI 0.5-0.9)。
- 肝硬化患者血栓后90天死亡率:静脉血栓栓塞17% vs 7%,急性心肌梗死27% vs 5%,缺血性卒中10% vs 7%。
关键数值与推荐
- 肝硬化患者中位MELD评分为9(四分位距7-13)。
- 肝硬化失代偿增加急性心肌梗死风险,但不增加其他血栓风险。
临床怎么用
- 肝硬化患者应关注静脉血栓栓塞和缺血性卒中风险,抗血栓预防决策需权衡血栓与出血风险。
- 肝硬化患者发生血栓后死亡率高,需加强监测和管理。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Cirrhosis affects hemostasis, but its effects across the spectrum of thromboses remain poorly understood. We examined risks and outcomes of venous and arterial thrombosis. APPROACH AND RESULTS: We used nation-wide Danish health care registries to identify outpatients with cirrhosis and a sex- and age-matched comparison cohort without cirrhosis from the general population. Patients with cirrhosis and comparators were followed until they had a venous thromboembolism (VTE), acute myocardial infarction (AMI), or ischemic stroke (IS) or died. We computed absolute risks and HRs of thrombosis and compared outcomes after thrombosis. We included 5,854 patients with cirrhosis (median Model for End-Stage Liver Disease score, 9; interquartile range, 7-13), and their risk of any of the thrombotic events was 0.8% after 1 year and 6.3% after 10 years. They were more likely than the 23,870 matched comparators to have a VTE (adjusted hazard ratio [aHR], 2.0; 95% CI, 1.5-2.6) or IS (aHR, 1.7; 95% CI, 1.3-2.3), but not AMI (aHR, 0.7; 95% CI, 0.5-0.9). Among patients with cirrhosis, decompensation increased the risk of AMI, but not the other thromboses. Following thrombosis, patients with cirrhosis had higher 90-day mortality than comparators (after VTE: 17% vs. 7%; after AMI: 27% vs. 5%; after IS: 10% vs. 7%) and were less likely to receive antithrombotic treatment. CONCLUSIONS: Patients with cirrhosis had an increased risk of VTE and IS, but not AMI. Among patients with cirrhosis, decompensation increased the risk of AMI, exclusively. Mortality after thrombosis was higher in patients with cirrhosis than in other patients. These findings are relevant for decisions about antithrombotic prophylaxis in patients with cirrhosis.
引用
- Jepsen P, Tapper EB, Deleuran T, et al. Risk and Outcome of Venous and Arterial Thrombosis in Patients With Cirrhosis: A Danish Nation-wide Cohort Study. Hepatology. 2021. PMID: 34137045. doi:10.1002/hep.32019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。